• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Rhythm Pharmaceuticals

edit

Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

Recent Milestones

edit

• 
  Rhythm Pharmaceuticals received $8M in Series B funding. (11/27/12)
  Posted 11/27/12 at 7:45pm via pehub.com
• 
  Rhythm Pharmaceuticals received $25M in Series B funding. (6/13/12)
  Posted 6/13/12 at 6:14pm via rhythmtx.com
• 
  Rhythm Pharmaceuticals received $9.5M in Venture Round funding. (6/4/12)
  Posted 6/4/12 at 5:56pm via masshightech.com
• 
  Rhythm Pharmaceuticals received $19M in Series A funding. (9/8/10)
  Posted 9/13/10 at 1:01am via genengnews.com
• 
  Rhythm Pharmaceuticals received $21M in Series A funding. (3/15/10)
  Posted 3/15/10 at 7:45pm via fiercebiotech.com
• 
  Rhythm Pharmaceuticals added Bart Henderson as President & Founder.
  Posted 3/15/10 at 7:45pm
• 
  Rhythm Pharmaceuticals added Elizabeth Stoner as Chief Development Officer & Founder.
  Posted 3/15/10 at 7:45pm
• 
  Rhythm Pharmaceuticals added Keith M. Gottesdiener as CEO.
  Posted 11/9/11 at 8:16pm

Videos

Screenshots

edit

Sources

1. Rhythm Pharma raises $21M for metabolic diseases (fiercebiotech.com) [edit]
2. Rhythm Adds $19M to Series A Round to Advance Peptide-Based Drugs (genengnews.com) [edit]
3. Rhythm Pharma sells $9.5M in equity financing (masshightech.com) [edit]
4. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics (rhythmtx.com) [edit]
5. Rhythm Adds $8M to Cap Series B at $33M (pehub.com) [edit]